Comparing ARWR and ALNY AAT clinical trials
I have a question for all the bio experts on this board.
I've been comparing ARWR's AAT clinical trial:
with the Alnylam AAT trial:
To a layman like me, they look pretty similar to each other, however, the former is phase 2/3, and the latter - phase 1/2. What are the differences that I am apparently missing?
Would really appreciate it if someone with the understanding of the field could comment on that. Thanks